C-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer

British Journal of Surgery

Volumn 100, Issue 4, 2013, Pages 490-496

  Kashiwagi, S ^a   Yashiro, M ^a   Takashima, T ^a   Aomatsu, N ^a   Kawajiri, H ^a   Ogawa, Y ^b   Onoda, N ^a   Ishikawa, T ^a   Wakasa, K ^a   Hirakawa, K ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BREAST TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873410592     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9021     Document Type: Article

References (31)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al., Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, et al., High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340-350.
3. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al., Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006; 5: 24.
4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10 869-10 874.
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al., Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
6. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, et al., Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006; 42: 3149-3156.
7. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V,. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007; 109: 1721-1728.
8. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
9. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al., Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
10. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al., Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271.
11. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO,. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007; 50: 434-438.
12. Rakha EA, Reis-Filho JS, Ellis IO,. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581.
13. Rakha EA, Reis-Filho JS,. Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med 2009; 133: 860-868.
14. Miettinen M, Lasota J,. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005; 13: 205-220.
15. Roskoski R Jr,. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005; 338: 1307-1315.
16. DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J, et al., Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther 1997; 4: 176-182.
17. Tonary AM, Macdonald EA, Faught W, Senterman MK, Vanderhyden BC,. Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer 2000; 89: 242-250.
18. Krams M, Parwaresch R, Sipos B, Heidorn K, Harms D, Rudolph P,. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene 2004; 23: 588-595.
19. Simon R, Panussis S, Maurer R, Spichtin H, Glatz K, Tapia C, et al., KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004; 10: 178-183.
20. Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, et al., A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br J Cancer 2006; 94: 1874-1878.
21. Chui X, Egami H, Yamashita J, Kurizaki T, Ohmachi H, Yamamoto S, et al., Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996; 73: 1233-1236.
22. Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A,. Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 1992; 52: 713-717.
23. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Ikeda K, Ogawa Y, et al., Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res 2011; 13: R122.
24. Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, et al., Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer 2010; 103: 249-255.
25. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, et al.,; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009; 7: 1060-1096.
26. Yamashiro H, Toi M,. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 2008; 13: 3-7.
27. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al., Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271.
28. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al., Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-2310.
29. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al., Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
30. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G,. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006; 37: 1217-1226.
31. Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP, et al., KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res 2008; 14: 2285-2294.